Press Releases

  • For Immediate Release

    Optispan CEO Matt Kaeberlein Named "Healthcare Innovator of the Year" by Puget Sound Business Journal

    Seattle, WA – 12/7/23 – Optispan, a leading healthcare technology company, proudly announces that the the Puget Sound Business Journal has named its CEO, Dr. Matt Kaeberlein, "Healthcare Innovator of the Year". This prestigious accolade was presented to Dr Kaeberlein at the PSBJ Healthcare Leadership Awards Luncheon held Thursday, December 7th at the Sheraton Grand Seattle.

    "It's an honor to receive this recognition from the Puget Sound Business Journal," Dr. Kaeberlein said. "This award is a testament to our team's dedication and hard work and our vision for a better healthcare future.”

    Under Dr. Kaeberlein's leadership, Optispan is building scalable technologies that enable science-based, healthspan medicine. “Optispan’s focus is fundamentally different from that of the traditional reactive disease care industry,” Dr. Kaeberlein said. “Our approach is laser focused on keeping people healthy rather than keeping people sick.”

    The PSBJ Healthcare Leadership Awards event is highly anticipated within the healthcare community. It brings together industry leaders, innovators, and practitioners to celebrate outstanding achievements in healthcare.

    Optispan's commitment to pioneering a new era of healthcare is unwavering. With Dr. Kaeberlein at the helm, the company continues to push the boundaries of medical science and technology, offering hope and practical solutions for healthier, longer lives.

    For more information about Optispan and its groundbreaking work in healthspan optimization, visit http://www.optispan.life.

    About Optispan

    Optispan is a healthcare technology company based in Seattle, Washington, committed to advancing Healthspan Medicine.

    Contact:

    Tara Mei
    Head of Strategy
    Optispan
    tara@optispan.life

  • For Immediate Release

    Optispan Collaborates in Groundbreaking RAPID Clinical Trial to Tackle Periodontal Disease and Aging

    Seattle, WA – 12/4/23 – Optispan, a leading healthcare technology company based in Seattle, is proud to announce its collaboration in the landmark RAPID clinical trial, which has received approval from the U.S. Food and Drug Administration (FDA). This pioneering study, led by Dr. Jonathan An at the University of Washington, aims to evaluate the effectiveness of rapamycin in older adults with periodontal disease, a chronic oral inflammatory disease linked to other age-related conditions such as heart disease, diabetes, and Alzheimer’s Disease.

    The RAPID trial stands out as the first and only study of its kind, targeting the mTOR pathway via rapamycin to attenuate, and potentially reverse, periodontal disease. This approach signifies a shift from merely addressing the symptoms of periodontal disease to tackling the underlying biological aging process.

    Optispan CEO, Dr. Matt Kaeberlein, expresses his enthusiasm for this collaboration: "We are thrilled to be part of the RAPID trial, a significant step in our mission towards Optimal Healthspans for Everyone. This trial embodies our commitment to proactive, science-based healthcare and marks a pivotal moment in the treatment of age-related diseases."

    Optispan’s Chief Medical Officer, Dr. George Haddad, adds, “Our participation in the RAPID trial aligns perfectly with our philosophy of Healthspan Medicine and our systems view of health. By monitoring biological aging biomarkers in participants, we aim to gather invaluable data that could redefine the understanding and management of periodontal disease and its systemic implications.”

    Enrolled participants in the RAPID trial will receive comprehensive exams, rapamycin treatment, and 3-4 dental cleanings, including deep cleanings, free of charge, in addition to compensation for their time. Optispan’s role in monitoring biological aging biomarkers is expected to provide critical insights into the broader health impacts of the treatment.

    For more information on the RAPID trial, to sign up as a participant, or to support through donations, please visit www.rapamycintrial.com.

    Optispan is excited to contribute to this groundbreaking research and hopeful that the results from the RAPID trial will advance next-generation treatment strategies for periodontal disease and enhance our understanding of the intricate relationship between oral health and aging.

    About Optispan

    Optispan is a healthcare technology company based in Seattle, Washington, committed to advancing Healthspan Medicine.

    Contact:

    Tara Mei
    Head of Strategy
    Optispan
    tara@optispan.life